Home > NCC joins GSK’s oncology development network
NCC joins GSK’s oncology development network
(back row, from left) Drs Tania Small, Hesham Abdullah, Susie Barnes, Christine Roth, Teiji Takei
(front row, from left) Drs Paul Lirette, Axel Hoos, Hitoshi Nakagama, Toshirou Nishida
National Cancer Center Japan has joined a collaborative research network launched by GlaxoSmithKline (GSK), concluded on 14 January 2020.
The Oncology Clinical and Translational Consortium (OCTC) comprises eight leading cancer centers around the world and GSK, formed to accelerate innovative oncology drug development employing clinical and scientific experience and the latest technology. The National Cancer Center became the latest addition, the first from Asia. Through this affiliation, multifaceted collaborations, including those on early phase - preclinical to Phase I clinical trials will gain momentum.
Drs Axel Hoos and Hiroyuki Mano at the biobank
meeting at Hospital East
Drs Axel Hoos and Hesham Abdullah at the early phase development unit